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Background: Nullbasic is a mutant HIV-1 Tat protein that inhibits HIV-1 replication via three independent mechanisms
that disrupts 1) reverse transcription of the viral RNA genome into a DNA copy, 2) HIV-1 Rev protein function required
for viral mRNA transport from the nucleus to the cytoplasm and 3) HIV-1 mRNA transcription by RNA Polymerase II. The
Nullbasic protein is derived from the subtype B strain HIV-1BH10 and has only been tested against other HIV-1 subtype B
strains. However, subtype B strains only account for ~10% of HIV-1 infections globally and HIV-1 Tat sequences vary
between subtypes especially for subtype C, which is responsible for ~50% HIV-1 infection worldwide. These differences
could influence the ability of Tat to interact with RNA and cellular proteins and thus could affect the antiviral activity of
Nullbasic. Therefore, Nullbasic was tested against representative HIV-1 strains from subtypes C, D and A/D recombinant
to determine if it can inhibit their replication.
Methods: Nullbasic was delivered to human cells using a self-inactivating (SIN) γ-retroviral system. We evaluated
Nullbasic-mCherry (NB-mCh) fusion protein activity against the HIV-1 strains in TZM-bl cell lines for inhibition
of transactivation and virus replication. We also examined antiviral activity of Nullbasic-ZsGreen1 (NB-ZSG1)
fusion protein against the same strains in primary CD4+ T cells. The Nullbasic expression was monitored by
western blot and flow cytometry. The effects of Nullbasic on primary CD4+ T cells cytotoxicity, proliferation
and apoptosis were also examined.
Results: The results show that Nullbasic inhibits Tat-mediated transactivation and virus replication of all the
HIV-1 strains tested in TZM-bl cells. Importantly, Nullbasic inhibits replication of the HIV-1 strains in primary
CD4+ T cells without affecting cell proliferation, cytotoxicity or level of apoptotic cells.
Conclusion: A SIN-based γ-retroviral vector used to express Nullbasic fusion proteins improved protein expression
particularly in primary CD4+ T cells. Nullbasic has antiviral activity against all strains from the subtypes tested although
small differences in viral inhibition were observed. Further improvement of in γ-retroviral vector stable expression of
Nullbasic expression may have utility in a future gene therapy approach applicable to genetically diverse HIV-1 strains.Background
The HIV-1/AIDS pandemic remains a huge social and
economic burden. By 2014, 36.9 million people were liv-
ing with HIV and 1.2 million AIDS related death cases
were reported [1]. One of the major obstacles in treating
this disease is a high genetic diversity of HIV-1 that
leads to different rates of disease progression and resist-
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and therefore may have efficacy against HIV-1 with di-
verse genetic backgrounds.
The agent is a Tat mutant protein derived from HIV-1
subtype B strain BH10 that strongly inhibits HIV-1 repli-
cation in human cells [4], and is referred to as Nullbasic.
Wild type Tat is an essential HIV-1 protein required for
transactivation of the HIV-1 long terminal repeat (LTR)
promoter resulting in high levels of viral mRNA tran-
scription by RNA polymerase II [5]. It also plays a role
in HIV-1 reverse transcription [6, 7] and in other cellularle is distributed under the terms of the Creative Commons Attribution 4.0
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flammatory cytokines and apoptosis [8–10]. Nullbasic,
which has been described previously [4, 11, 12], has a
substitution mutation spanning the entire basic domain;
amino acids 49 to 57, RKKRRQRRR, are replaced with
GGGGGAGGG. Studies show that Nullbasic expressed
in cells is located in the nucleus and cytoplasm [13], and
inhibits HIV-1 replication by 1) inhibiting HIV-1 tran-
scription by RNA polymerase II through interaction with
the positive transcription elongation factor (p-TEFb) and
causing epigenetic silencing of the HIV-1 LTR promoter
[4, 12, 13], 2) inhibiting Rev-dependent viral mRNA
transport from the nucleus by binding to DEAD/H-box
helicase 1 (DDX1) [13, 14], and 3) inhibiting reverse
transcription by directly interacting with reverse tran-
scriptase (RT) leading to accelerated uncoating kinetics
post-infection and defective viral DNA synthesis [15].
HIV-1 sequence diversity is categorized by HIV-1 sub-
types that are defined by comparisons of envelope genes.
These subtype variations can also be observed as differ-
ences in viral proteins, such as Tat, Rev and RT. Amino
acid sequence variation in the viral proteins of various
HIV-1 subtypes can affect virus replication and virulence
[16]. For example, RT from subtype C isolates differs
from subtype B by ~7–10%, which can affect drug sus-
ceptibility and cause drug resistance [16]. Tat proteins
from different subtypes can vary up to 40% without sig-
nificantly affecting Tat transactivation ability [17], but
the effects on many alternative functions of Tat [18]
have not been studied in detail.
To date, Nullbasic antiviral activity has only been
tested against HIV-1 subtype B strains such as HIV-
1NL43 [4, 11]. However, subtype B strains only accounts
for ~10% of HIV-1 infections globally and HIV-1 Tat
sequences vary between subtypes especially for subtype
C, which is responsible for ~50% HIV-1 infection world-
wide [19, 20]. Subtype C is predominant in sub Saharan
Africa, India and South America [21], while subtype D
and recombinant A/D are increasing in sub-Saharan
Africa [22, 23]. Whether sequence variations in different
HIV-1 subtypes alter the susceptibility to the antiviral ef-
fect of Nullbasic has not been examined. Therefore, in
this study, Nullbasic ability to inhibit replication of HIV-
1 strains from different subtypes including C, D and A/
D was evaluated. To enable protein expression detection
in the targeted cells, Nullbasic was tested in the form of
fusion proteins as NB-mCh [13] or NB-ZSG1 [11].
Methods
Cell lines and cultures
HEK 293T (ATCC), TZM-bl [24, 25] and Phoenix-Ampho
[26] cell lines were grown in Dubelcco’s modified Eagle’s
medium (DMEM; Life Technologies) supplemented with
10% (v/v) fetal bovine serum (FBS), penicillin (100 IU/ml)and streptomycin (100 μg/ml) (referred to as DF10
medium). TZM-bl expressing NB-mCh or mCh cell lines
were established by transduction of NB-mCh or mCh
virus-like particles (VLPs) and then selected by fluor-
escent activated cell sorter (FACS) for the top 10% of
mCherry positive cells by mean fluorescent intensity
(MFI).
Peripheral blood mononuclear cells (PBMCs) were
isolated from healthy donor’s buffy coat supplied by
Australian Red Cross Blood service using Ficoll dens-
ity gradient centrifugation. CD4+ cells were isolated
from the PBMCs by using a magnetic-activated cell sort-
ing human CD4+ cell isolation kit (Miltenyi Biotec) as per
the manufacturer’s instruction. The selected cells were
grown in 6 cm tissue culture dishes and stimulated using
plates pre-coated with purified anti-human CD3 (clone
HIT3a) and anti-human CD28 (clone CD28.2) antibodies
(BioLegend) in RPMI medium supplemented with 20%
(v/v) FBS and 5 ng/ml interleukin-2 (IL-2) (hereafter called
RF20 IL-2) for 2 days. All cells were grown at 37 °C in
humidified incubators with 5% CO2.
Plasmids constructs
pSRS11-SF-γC-EGFP was a gift from Axel Schambach
and Christopher Baum [27]. pSRS11-SF-γC-NB-mCh or
pSRS11-SF-γC-mCh or pSRS11-SF-γC-NB-ZSG1 or
pSRS11- SF-γC-ZSG1 construct was made by replacing
the enhanced green fluorescent protein gene in pSRS11-
SF-γC-EGFP with NB-mCh or mCh or NB-ZSG1 or
ZSG1. A proviral plasmid pGCH making HIV-1NL43
(GenBank accession number AF324493) was previously
described [13]. The proviral plasmid pZAC (GenBank
accession number JN188292.1) was obtained from
Jochen Bodem [28]. The proviral plasmids pELI and
pMAL (Los Alamos accession number A07108 and
A07116 respectively) were provided by Damian Purcell
[29]. The exon tat genes with hemagglutinin epitope
were synthesized by GenScript and ligated into
pcDNA3.1+ plasmid (Thermofisher Scientific).
HIV-1 and VLPs production
HIV-1 subtype B, C, D and A/D were produced from
pGCH, pZAC, pELI and pMAL proviral plasmids re-
spectively. HEK 293 T cells were grown on a 10 cm plate
at ~80% confluency and transfected with 10 μg of each
proviral plasmid then incubated for 24 h at 37 °C. On
the next day, the transfected cells were washed with 1 x
phosphate buffered saline (PBS) and the DF10 media
was replaced. The supernatant containing HIV-1 VLPs
was collected 48 and 72 h post transfection and the
amount of HIV-1 capsid (CA) protein in each super-
natant was measured by enzyme-linked immunosorbent
assay (ELISA) (Zeptometrix) as recommended by the
manufacturer.
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produced in Phoenix-amphotropic retroviral packaging
producer cell line by co-transfection of 7.5 μg of
pSRS11-SF-γC vector expressing NB-mCh or mCh or
NB-ZSG1 or ZSG1 and 1.5 μg of Gag-Pol expressing
plasmid using X-tremeGENETM DNA transfection re-
agent (Roche) in a 10 cm plate. Six hours post transfec-
tion, the cells were washed with PBS and the media was
replaced. The VLPs were collected 48 and 72 h post
transfection and filtered through a 0.45 μm filter.
Western blot analysis
Cell lysates were made from 5 × 106 NB-mCh or mCh-
TZM-bl cells, or from 3 × 106 CD4-NB-ZSG1, CD4-
ZSG1 or non-transduced CD4 cells in cell lysis buffer
(50 mM Tris HCl pH 7.4, 150 mM NaCl, 1 mM ethyl-
enediaminetetraacetic acid and 1% (v/v) Triton X-100).
The total protein concentration was measured by a
Bradford assay using Bio Rad protein assay (Bio Rad)
and equivalent amounts of protein were used for ana-
lysis. The blots were stained with a anti-mCherry rabbit
antibody (BioVision), a rabbit anti-Tat antibody (Dia-
theva), a mouse anti-ZsGreen1 (Origene), a rabbit anti-
β-tubulin antibody (Sigma Aldrich), or a goat anti-actin
antibody (Santa Cruz) as indicated. Appropriate species-
specific secondary antibodies conjugated to horse radish
peroxidase (HRP) (Cell Signaling Technology) and
followed detection by chemiluminescence (BioRad).
Transactivation assay
Tissue culture dishes (6 cm) were seeded with 5 × 105
TZM-bl cells expressing NB-mCh or mCh and then co-
transfected with 1 μg of each subtype Tat plasmid or
pCDNA3.1+ without an insert and 150 ng of Gaussia
luciferase expression plasmid. After 48 h, the cells were
washed with PBS and cell lysates were made using Glo
Lysis buffer (Promega). Luciferase assays were per-
formed in 96 well white polystyrene microplates as per
the manufacturer’s instructions using 10 μl of the cell
lysates and Dual-Glo® luciferase substrate (Promega).
Luciferase activity in each sample was measured within
20 min by using a luminescence microplate reader and
relative values were normalized to Gaussia luminescence
in the sample.
Next, 3 × 105 TZM-bl cells expressing NB-mCh or
mCh or non-transduced (NT) TZM-bl cells were seeded
in 6 well plates. The next day, the cells were infected
with HIV-1NL4–3 (subtype B), HIV-1ZAC (subtype C)
[28], HIV-1ELI (subtype D) and HIV-1MAL (A/D recom-
binant subtype) virus supernatant containing 20 ng of
CA, or a mock supernatant for 48 h. The cells were
washed with PBS and then cell lysates were made using
Glo Lysis buffer (Promega). Luciferase activity was mea-
sured as described above.Transduction of NB-ZSG1 or ZSG1 VLP in CD4+ T cells
NB-ZSG1 or ZSG1 VLPs were concentrated using the
precipitation method through the addition of 20% (v/v)
of 34% polyethylene glycol 8000 (Sigma Aldrich) and
10% (v/v) of 0.3 M NaCl solution. The solution mixture
was incubated at 4 °C for 1.5 h, mixed every 30 min and
then centrifuged at 1500 × g for 1 h at 10 °C. The super-
natant was discarded and the precipitate was resus-
pended in 600 μl RF20 IL-2 medium. The concentrated
VLP (150 μl) was added to Retronectin (Takara) coated
24 well plate and incubated at 37 °C for 30 min. 5 × 105
stimulated CD4+ cells were added to each well and incu-
bated for 3 days. Transduced cells were processed by
FACS to collect ZSG1 positive cells which were grown
for 3 days further. The RF20-IL2 media was replaced
every day.
Infection of HIV-1NL4–3 (subtype B), HIV-1ZAC (subtype C),
HIV-1ELI (subtype D) and HIV-1MAL (A/D recombinant
subtype) in TZM-bl cell lines and primary CD4+ T cells
TZM-bl cells expressing NB-mCh or mCh or NT (3 ×
105 cells/well) cultured in a 6 well plate were infected
with a virus stock containing 20 ng CA of HIV-1NL4–3,
HIV-1ELI and HIV-1MAL or 40 ng CA of HIV-1ZAC, or a
mock supernatant for 2 h at 37 °C. A larger amount of
HIV-1ZAC was required to yield measurable infections.
The virus was then removed by washing the cells 3 times
with PBS and the infected cells were cultured at 37 °C
with 5% of CO2. The culture supernatants were sampled
on day 3 and 5 post infection. The amount of HIV CA
present was measured using a CA ELISA kit (Zeptome-
trix) according to the manufacturer’s instruction.
Primary CD4+ T cells (5 × 105 NB-ZSG1 or ZSG1 or
NT) were infected with virus stocks containing 2 ng CA
of each HIV-1 subtype for 2 h at 37 °C. After infection,
the cells were washed with PBS and cultured in RF20
IL-2 medium. Cell and supernatant samples were col-
lected on days 0, 3, 7, 10 and 14 by centrifugation at
500 × g for 5 min. The amount of viral CA in the super-
natant was measured by ELISA. The cells were fixed
with 1% paraformaldehyde in PBS solution and NB-
ZSG1 or ZSG1 expression was measured by flow
cytometry.
Cytotoxicity assays
Cell metabolic activity was measured by MTS assay using
a CellTiter 96® aqueous one solution cell proliferation
reagent (Promega) according to the manufacturer’s in-
structions. Cell proliferation was quantified using a Violet
Proliferation Dye 450 (BD HorizonTM) assay in accord-
ance with the manufacturer’s instructions and violet fluor-
escence was measured using a violet laser-equipped BD
LSRFortessaTM IV flow cytometer. Apoptosis events were
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Fig. 1 Expression of Nullbasic-mCherry (NB-mCh) and mCherry (mCh)
in TZM-bl cells. a A schematic of the NB-mCh amino acid sequence.
The basic domain of wild type Tat was mutated to glycine or alanine
residues as shown (green) and other domains are labeled. b A
schematic diagram of SIN γ-retroviral SRS11-SF-γC vector showing
NB-mCh or mCh that are expressed by a SFFV internal promoter. Rous
Sarcoma Virus (RSV) promoter is used to transcribe mRNA for packaging
in VLPs. The woodchuck hepatitis virus post transcription regulatory
element (WPRE) was inserted adjacent to NB-mCh or mCh to enhance
gene expression. c Purity of selected TZM-bl cells expressing NB-mCh
or mCh analyzed by flow cytometry. d NB-mCh and mCh expression in
TZM-bl cells was detected by a Western Blot using anti-mCherry
antibody. The blot was also stained with an anti-β tubulin antibody
Rustanti et al. Virology Journal  (2017) 14:52 Page 4 of 11(BD PharmingenTM) as per the manufacturer’s instruc-
tions. Camptothecin, which induces apoptosis in CD4+ T
cells, was used as a positive control.
Statistical analysis
Mean values of percentage of transactivation inhibition
between strains were compared using Kruskal-Wallis
one-way analysis of variance. A 95% confidence interval
was used, therefore a p value less than 0.05 was consid-
ered to be significant.
Results
Inhibition of transactivation and replication of HIV-1
strains from diverse subtypes in TZM-bl cells by NB-mCh
fusion protein
A schematic diagram of Nullbasic protein and the basic
domain mutations (amino acids 49–57) to glycine and
an alanine are shown in Fig. 1a. A NB-mCh fusion
protein, used previously to investigate Nullbasic inhib-
ition on HIV-1 Rev activity [14], was inserted into a
SIN γ-retroviral vector pSRS11-SF-γC (Fig. 1b) [27].
VLPs produced in Phoenix amphotropic packaging
cells [30] were used to transduce TZM-bl cells and
those stably expressing NB-mCh or mCh (hereafter
referred to as TZM-bl-NB-mCh or TZM-bl-mCh, re-
spectively) were collected by FACS. Expression of
NB-mCh and mCh was confirmed by flow cytometry
analysis of the purified cells (Fig. 1c) and western blot
analysis using an anti-mCherry antibody (Fig. 1d).
It is worth reviewing the amino acid sequence hetero-
geneity of Tat from these different strains by comparing
the alignment of Tat proteins from HIV-1NL4–3 (subtype
B), HIV-1ZAC (subtype C) [28], HIV-1ELI (subtype D)
and HIV-1MAL (A/D recombinant subtype). The four
different amino acid sequences have amino acid residue
substitutions in all domains except for amino acids 43 to
56 (Fig. 2, boxed), which includes the basic domain,
completely conserved. The first 20 residues of each Tat
protein include 17 positions that are conserved or func-
tionally similar. The carboxyl terminal amino acids 90 to
100 of subtype C and D Tat proteins have conserved
amino acid sequences KKKVE and ETDP (Fig. 2, under-
lined), which are also present in Nullbasic (derived from
HIV-1BH10). All four Tat proteins maintained the cyst-
eine residues in the cysteine-rich domain with one ex-
ception; HIV-1ZAC (subtype C) has a C31S substitution.
Tat mediates HIV-1 transactivation by binding to
trans-activation response (TAR) RNA in the R region of
HIV-1 LTR and recruiting P-TEFb [31] that then binds a
super elongation complex (SEC) [32, 33]. P-TEFb con-
sists of cyclin T1 and cyclin dependent kinase 9 (CDK9)
[31]. In Tat, K41 is important for intramolecular hydro-
gen bonding and structural integrity of the Tat core [34]
and is present in all Tat proteins shown except HIV-1ZAC which has T41. A crystal structure of the Tat-P-
TEFb complex showed that the surface of 37% amino
acids 1–49 are complementary to the kinase complex,
and this model indicates that the interactions between
Tat and P-TEFb can accommodate substitutions com-
monly present in different Tat genes [34]. However, Tat
interacts with other cellular proteins many of which are
important for HIV transcription [35]. Therefore, it is
possible that these subtle differences could affect the
ability of Nullbasic to inhibit the transactivation by Tat
from the HIV-1 strains shown.
To test if transcription by Tat from different HIV-1
strains can be inhibited by Nullbasic, TZM-bl-NB-mCh
and TZM-bl-mCh cell lines stably carrying a HIV-1-LTR
firefly luciferase reporter were co-transfected with
eukaryotic expression plasmids that express either
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Fig. 2 A comparison of Nullbasic amino acid sequence against an amino acid sequence alignment for TatBH10, TatNL4–3, TatZAC, TatELI and TatMAL.
Amino acids highlighted in yellow are conserved for the Tat variants. TatZAC amino acid residue S31 and T41 are circled (blue)
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control for transfection efficiency. Tat can activate the
HIV-1-LTR firefly luciferase reporter in TZM-bl cell
lines, while Gaussia luciferase reporter enables linear
quantification of relative transfection efficiencies
between samples [36]. The amount of firefly luciferase
activity present in lysates from the transfected TZM-bl
cells was measured and the relative luminescence unit
(RLU) values were normalized to Gaussia luciferase
RLUs measured in the culture supernatant. The results
show that expression of NB-mCh in TZM-bl-NB-mCh
cells reduced transactivation of the HIV-1 LTR luciferase
reporter in all subtypes tested from ~70 to ~90% (Fig. 3).
Although TatZAC showed a trend towards less inhibition
than others, this difference did not achieve statistical sig-
nificance. Transfection of an empty expression plasmid
did not affect the level of luciferase made by TZM-bl-



























Fig. 3 NB-mCh inhibits Tat-mediated transactivation after transfection of
TZM-bl by Tat from different strains. TZM-bl cell lines expressing NB-mCh
or mCh were transfected with pCDNA3.1+ containing each Tat variant
or with empty pCDNA3.1+ A Gaussia luciferase expression plasmid was
co-transfected as a control for transfections efficiency. Luciferase activity
was measured 48 h post transfection. Bars indicate mean percentage of
transactivation inhibition by NB-mCh compared to mCh cells from two
independent experiments each carried out in triplicate. The p value of
the data set is shownthe level of Nullbasic inhibition of the Tat proteins
tested here was similar to a previous report [4].
Post infection, the integrated provirus produced Tat can
activate the HIV-1-LTR luciferase reporter in TZM-bl
cells, which is an indicator of virus infection and replica-
tion. To evaluate Nullbasic inhibition of Tat-mediated
transactivation of different HIV-1 strains, we infected
TZM-bl-NB-mCh and TZM-bl-mCh cells with HIV-
1NL4–3 (subtype B), HIV-1ZAC (subtype C), HIV-1ELI
(subtype D) and HIV-1MAL (recombinant A/D sub-
type) produced in HEK293T cells or with mock
supernatant. Lysates prepared from HIV-1 infected
TZM-bl cells 48 h post infection were assayed for
firefly luciferase activity and the results were normal-
ized to total protein concentration in the cell lysates.
NB-mCh significantly reduced the amount of RLUs
produced compared to control lysates made from in-
fected TZM-bl-mCh cells. HIV-1NL4–3 viral Tat trans-
activation of the LTR-luciferase reporter was inhibited
by ~97%; slightly lower inhibitions of transactivation
were measured for all other HIV-1 strains; HIV-1ZAC
by ~90%, HIV-1ELI by ~89% and HIV-1MAL by ~91%
(Fig. 4). However, the difference between transactiva-
tion inhibition in HIV-1NL4–3 and other strains did
not achieve statistical significance. The level of lucif-
erase made by mock-infected TZM-bl-NB-mCh cells
compared to TZM-bl-mCh cells was unchanged. The
combined experiments demonstrate that NB-mCh can
inhibit transactivation of the TZM-bl LTR reporter by
each Tat tested albeit at a slightly reduced level com-
pared to HIV-1NL4–3.
Finally, we tested if the presence or absence of NB-
mCh could inhibit viral replication (rather than assessing
effects on the integrated HIV-1 LTR-luciferase reporter
in the cell line) of each HIV-1 strain in the TZM-bl cell
lines. In this 5 day experiment, detection of CA by
ELISA requires virus replication. Therefore, TZM-bl-
NBmCh and TZM-bl-mCh cells were infected, superna-
tants were collected on day 3 and 5 post infection, and
the amount of CA in each sample was by measured by




























Fig. 4 NB-mCh inhibits Tat-mediated transactivation after infection
of TZM-bl by different HIV-1 subtypes. TZM-bl cell lines expressing
NB-mCh or mCh were infected with each HIV-1 strain or with mock
supernatant. Luciferase activity was measured 48 h post infection
and normalized to total protein in the sample. Bars indicate mean
percentage of transactivation inhibition by NB-mCh compared to
mCh cells. Error bars indicate standard deviation of three independent
experiments carried out in triplicate. The p value of the data set
is shown
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mCh cells with an increasing level of CA from day 3 to
5. However, HIV-1 replication of all strains was inhibited
in TZM-bl-NBmCh cells. Comparing day 5 CA levels by
TZM-bl-mCh to TZM-bl-mCh cells showed the produc-


































Fig. 5 NB-mCh inhibits virus replication of all the HIV-1 strains tested in TZM-
with each HIV-1 strain; a HIV-1NL4–3 (subtype B), b HIV-1ZAC (subtype C), c HIV-
5 days infection, culture supernatant was assayed for HIV-1 CA by ELISA. The e
deviations are shown from two independent experiments3, ~97% for HIV-1ZAC, ~98% for HIV-1ELI, and ~97% for
HIV-1MAL. As previously observed, the trend was that
NB-mCH inhibited HIV-1NL4–3 better than other strains
tested. Nevertheless, the combined results support the
hypothesis that Nullbasic can inhibit virus replication of
the HIV-1 strains tested in TZM-bl cells.
Antiviral activity of Nullbasic-ZsGreen1 (NB-ZSG1) in
primary CD4+ T cells against 4 HIV-1 subtypes
We previously used an MLV-based γ-retroviral vector,
pGCsamEN [11], containing NB-ZSG1 or ZSG1 to
transduce primary CD4+ cells. In those experiments,
cells that expressed NB-ZSG1 significantly delayed HIV-
1NL4–3 replication compared to cells expressing ZSG1.
However, pGCsamEN is not a SIN vector and expres-
sion of a transgene is via the MLV-LTR promoter.
Non-SIN γ-retroviral vector can be transcriptionally re-
pressed in cells [37], which can be lessened by SIN-based
γ-retroviral vectors that used strong constitutively
expressed internal promoters. Therefore, SRS11-SF-γC-
NB-ZSG1 VLPs were used to transduce CD4+ T cells in
this study. The transduced CD4+ T lymphocytes were
selected by FACS using parameters previously de-
scribed and a western blot was performed to confirm
NB-ZSG1 and ZSG1 expressions (hereafter referred to
as CD4-NB-ZSG1 and CD4-ZSG1, respectively) in the
sorted cells (see Additional file 1).
CD4-NB-ZSG1, CD4-ZSG1 and NT CD4 cells were


































bl cells. TZM-bl cell lines expressing NB-mCh or mCh or NT were infected
1ELI (subtype D) and d. HIV-1MAL (recombinant A/D subtype). After 3 and
xperiment was performed in triplicate and mean values and standard
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were inhibited but some strain specific differences were
noted. For example, HIV-1NL4–3, HIV-1ZAC, and HIV-
1ELI were strongly inhibited. At day 14 post infection, in
CD4-ZSG1 to CD4-NB-ZSG1 cells, CA levels reduced
by 90% for HIV-1NL4–3, and 88% for HIV-1ELI and HIV-
1MAL. However, no CA was detected after infection with
HIV-1ZAC. It is worth noting that based on CA expression
levels, this HIV-1ZAC replicated poorly in TZM-bl (Fig. 5b)
and CD4+ T cells (Fig. 6b). Compared to HIV-1NL43, HIV-
1ZAC replication in CD4+ T cells on day 14 post infection
was ~100-fold lower. A reduced level of HIV-1ZAC replica-
tion compared to HIV-1NL4–3 was reported previously
[28]. Therefore, this may account for a lack of detectable
CA by HIV-1ZAC in CD4-NB-ZSG1 cells.
NB-ZSG1 and ZSG1 expression was monitored in un-
infected and HIV-1-infected CD4+ T cells by flow cy-
tometry. CD4+ T cell populations were initially collected
by FACS so that ZSG1 positive cell population was
>97%. The percentage of ZSG1 positive cells in the
population by 14 days ranged from 90% (for HIV-1ELI)
to 99% (uninfected CD4+ T cells) in all experiments,
whereas NB-ZSG1 levels were approximately 82% in un-
infected and infected CD4+ T cells (Fig. 7). However,
NB-ZSG1 expression reported here was much higher
than in previous experiments using pGCsamEN vectors
where the percentage of CD4+ T cells expressing NB-




































Fig. 6 NB-ZSG1 inhibits virus replication of all the HIV-1 strains tested in prim
ZSG1 were infected with each HIV-1 strain; a HIV-1NL4–3 (subtype B), b HIV-1ZA
subtype). The experiment was performed in triplicate and culture supernatant
post infection. Mean values and standard deviations from two independent eWe investigated if high level expression of NB-ZSG1
in CD4+ T cells had a measurable detrimental effect that
could explain why levels of NB-ZSG1 positive cells
declined. First, cell viability was evaluated by an MTS
colorimetric assay. This assay measures cellular metabol-
ism based on reduction of the MTS tetrazolium com-
pound by NAD(P)H-dependent oxydoreductase enzymes
largely in the cytosolic compartment of dividing cells
[38, 39]. No significant difference between CD4-
NBZSG1 and CD4-ZSG1 cells were found, although
both NB-ZSG1 and ZSG1 cells had a slightly lower
metabolic activity than NT cells, suggesting the trans-
duction, cell purification processes or ZSG1 were
responsible (Fig. 8a). Second, we measured cell prolifera-
tion using a cell permeable VPD450 dye for monitoring
of cell division by flow cytometry. No difference in pro-
liferation was observed between CD4-NB-ZSG1 and
CD4-ZSG1 (Fig. 8b). Given that HIV-1 wild type Tat is
reported to have pro- and anti-apoptotic activities in pri-
mary CD4+ T cells (reviewed in [40]), an annexin V assay
was used to determine if NB-ZSG1 expression affected
cellular apoptosis. All of the cells tested had very little or
no apoptosis (Fig. 8c), therefore we cannot account for a
drop in NB-ZSG1 levels in CD4+ T cells due detrimental
effects of NB-ZSG1 on the cellular pathways tested.
However, Nullbasic may affect other cellular pathways
other than those tested leading to reduced levels of Null-
basic expression in the cells.ZAC
NTZG
MAL































ary CD4+ T cells. CD4+ T cells (NT) or CD4+ T cells expressing NB-ZSG1 or
C (subtype C), c HIV-1ELI (subtype D) and d. HIV-1MAL (recombinant A/D
from each replicate was assayed by ELISA for CA on day 3, 7, 10 and 14














































































































































Fig. 7 A temporal analysis of NB-ZSG1 or ZSG1 expressed in CD4+ T cells. The percentage of NB-ZSG1 or ZSG1 positive cells in the CD4+ T cells
population infected by a HIV-1NL4–3 (subtype B), b HIV-1ZAC (Subtype C), c HIV-1ELI (Subtype D) d HIV-1MAL (A/D recombinant subtype) and e uninfected
CD4+ T cells was monitored by flow cytometry on day 3, 7, 10 and 14 post infection. Mean values and standard deviations from two independent
experiments performed in triplicates are shown
Rustanti et al. Virology Journal  (2017) 14:52 Page 8 of 11In summary, here we show that Nullbasic can inhibit
replication of HIV-1 strains from different subtypes.
The outcome indicates that the replication pathways
affected by Nullbasic are most likely shared by these
HIV-1 strains.
Discussions
In this study, we investigated if Nullbasic could inhibit
viral gene expression and virus replication of four differ-
ent strains representing four HIV-1 subtypes in human
cells. We previously showed that Nullbasic has three
independent antiviral properties at different stage of
HIV-1 replication cycle [4]; 1) inhibition of transactiva-
tion of virus gene expression by HIV-1 Tat [4, 11], 2) in-
hibition of HIV-1 Rev activity by sequestration of DDX1
[12, 13], and 3) binding to HIV-1 reverse transcriptase
in the virion leading to premature uncoating and defect-
ive reverse transcription in newly infected cells [14].
Given that Nullbasic inhibits HIV-1 by binding to both
cellular (P-TEFb and DDX1) and viral (RT) targets, we
found that, as expected, NB fusion proteins had antiviralactivity against all strains tested although some small dif-
ferences were observed.
Using TZM-bl cells, the effect of Nullbasic on transac-
tivation and virus replication was examined in three
ways. Briefly, wild type Tat mediates HIV-1 transactiva-
tion by binding and recruiting the SEC and P-TEFb
(composed of cyclin T1 and CDK9) to nascent viral
mRNA where CDK9 can phosphorylate RNA polymer-
ase II leading to highly processive RNA transcription
[31]. A crystal structure of the Tat-P-TEFb complex
showed that Tat tightly binds to P-TEFb as 37% of its
folded N-terminal domain (amino acids 1–49) surface is
complementary to the kinase. In Nullbasic, amino acids
1–48 are wild type but amino acids 49–57 are mutated.
Hence, Nullbasic is able to bind P-TEFb [13], but not re-
cruit the protein complex to nascent viral mRNA, which
requires the RNA binding function of the Tat basic
domain (amino acids 49–57) [8].
Firstly, in TZM-bl transfection experiments where
equivalent amounts of each Tat expression plasmid were























































Fig. 8 NB-ZSG or ZSG expression does not affect CD4+ T cell viability,
proliferation or induce apoptosis. a An MTS assay was used to measure
the viability of CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT. b The
proliferation of CD4+ T cells expressing NB-ZSG1 or ZSG1 or NT
was measured using VPD450 dye assay. c An apoptosis assay
using PE Annexin V was used to monitor levels of apoptosis in CD4+ T
cells expressing NB-ZSG1 or ZSG1 or NT. All assays were performed in
triplicate and mean values and standard deviations are shown
Rustanti et al. Virology Journal  (2017) 14:52 Page 9 of 11similar range (70–90% inhibition), but TatZAC was con-
sistently inhibited the least by NB-mCh. Interestingly, a
consensus subtype C Tat was reported to have superior
transactivation capacity compared to a consensussubtype B Tat [41], whereas TatZAC was a weaker tran-
scriptional activator here compared to the other Tat
proteins tested. This may be due to a TatZAC K41T substi-
tution that may affect TatZAC structure and interaction be-
tween TatZAC and P-TEFb [8]. Secondly, TZM-bl cells
were infected by each HIV-1 strain and transactivation of
the TZM-bl LTR-luciferase reporter was inhibited at simi-
lar levels (~90% inhibition of TatZAC, TatELI and TatMAL).
Thirdly, replication of all four viral strains was strongly
inhibited by NB-mCh, which ranged from 97 to 99%. It is
interesting that NB-mCh inhibited virus replication of
each strain better than it inhibited transactivation LTR-
Luciferase reporter, but the reason for this is unclear. It
could be due to Nullbasic effects on Rev activity or reverse
transcription, or perhaps differences in the TAR RNAs of
the various viral strains. Further work will be required
to elucidate the reasons. The data clearly shows that
viral transcription and replication mediated by the
four different Tat variant proteins, representing differ-
ent HIV-1 subtypes, was inhibited by NB-mCh under
the conditions tested.
The replication of all HIV-1 strains in stimulated pri-
mary CD4+ T cells was also inhibited by Nullbasic, but
differences were noted here too. The replication of HIV-
1ZAC in the presence of NB-ZSG1 was below the limit of
detection (~4 pg/ml), whereas HIV-1NL4–3, HIV-1ELI and
HIV-1MAL were strongly inhibited. We also noted that
although the FACS isolated CD4-NB-ZSG1 and CD4-
ZSG1 cells were >97% ZSG1 positive, the percentage of
ZSG1 positive cells was maintained by CD4-ZSG1 popu-
lation over 14 days whereas the percentage of ZSG1
positive cells in the CD4-NB-ZSG1 population decreased
by about 10–20%. Our data indicates that cell proliferation
of CD4-NB-ZSG1 and CD4-ZSG1 are similar, and levels
of cytotoxic effects and apoptotic cells were unchanged as
well. NB-ZSG1 may affect cellular pathways other than
those assayed. For example, we recently reported that NB-
ZSG1 strongly suppressed HIV-1 transcription in Jurkat
cells [12], so one possible cause of this NB-ZSG1 de-
creased expression level is that NB-ZSG1 also negatively
affects transcription by the constitutively active spleen
focus-forming virus (SFFV) promoter. Given that NB-
ZSG1 is able to target P-TEFb, it may impede an SEC
required for HIV-1 transcription [42], and perhaps SEC
complexes that stimulate transcription by the SFFV pro-
moter as well. Testing these possibilities will require deter-
mining if the NB-ZSG disrupts the P-TEFb-SEC
complexes, and further understanding of transcriptional
activation of the SFFV promoter.
Our data shows that HIV-1 replication increased in
CD4-NB-ZSG1 cells as the percentage of NB-ZSG1 posi-
tive CD4 T cells decreased, as we observed previously
[11]. It is possible that alternative promoters used to ex-
press Nullbasic in the retroviral vector may provide
Rustanti et al. Virology Journal  (2017) 14:52 Page 10 of 11sustained expression of NB-ZSG1, and lead to better
viral control. In addition, it would be also interesting to
introduce a Nullbasic-type mutation into other Tat vari-
ants and test if a strain-specific custom Nullbasic gene is
a better inhibitor of specific strains.
Conclusions
SIN-based γ-retroviral vectors improved expression of
Nullbasic and inhibited HIV-1 replication. The study
shows that Nullbasic can inhibit replication of the HIV-1
strains from different HIV-1 subtypes tested in TZM-bl
cells line as well as in primary CD4+ T cells. Stable expres-
sion of Nullbasic may have utility in a future gene therapy
approach applicable to genetically diverse HIV-1 strains.
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